Abstract
This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies reporting our pre-specified outcomes. It was observed that mavacamten significantly improved New York Heart Association class (p<0.009), Clinical Summary Score of theKansas City Cardiomyopathy Questionnaire(p=0.02), post-exercise left ventricular outflow tractgradient (p<0.00001), functional end point (p=0.05), and lowered septal reduction therapyrates (p<0.00001). However, there were no significant differences in the ≥1 severe adverse events, ≥1 treatment-emergent adverse events, left ventricular volume index, left ventricularfilling pressure, left ventricular end-diastolic volumeindex, and peak oxygen uptake(pVO2). Future large-scale trials are required to confirm our results and determine the long-term benefits and risks of mavacamten use in these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.